Development and Commercialization of a Novel Modified Release Tablet Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Development and Commercialization of a Novel Modified Release Tablet Technology
GlaxoSmithKline recently developed a novel technology for the formulation of modified-release tablets. Commercialized as DiffCORE, the technology combines the use of apertures that are mechanically drilled into functional film-coated tablets, with traditional polymer matrices that control the mechanism of core erosion and diffusion. The authors describe the route from development to commercialization of this modified-release approach.


Pharmaceutical Technology
Volume 36, Issue 12

What controls do you need over the apertures?

GSK identified four potential quality attributes throughout the development lifecycle to ensure consistent and robust performance of the product: presence, size, position, and depth of the apertures.

The effect these have on the performance of the product are dependent on the API and core formulation. Those products with greater robustness are evidenced by a wide tolerance of the aperture size ( 1 mm) with little impact of aperture position and depth, which provides a broad manufacturing control strategy using generic process controls. Those products that require more rigorous process controls around the aperture formation will require a unique process recipe, for instance, a high sensitivity to aperture depth, 10 m, would require specific drill movement parameters to ensure precise aperture formation. Typical process controls maintain the aperture size within 0.2 mm, the position to within 0.3 mm and the depth to within 50 m of target.

The online inspection systems, visual imaging, and laser displacement, measure every aperture formed in terms of size, position, and depth. The recipe-controlled specifications are used to categorize the product as acceptable or nonacceptable. Products that do not meet the specification are automatically removed from the process flow with a confirmation of removal. During routine production, the current process efficiencies are being measured at greater than 99.9%.

Does the drilling process affect uniformity or stability?


Figure 4: Dissolution performance of the initial product and after 56 months storage at 30 C/65 % relative humidity (RH).
For the products developed to date, GSK typically observed no change in release profile on stability for the drilled products. Figure 4 shows stability dissolution performance of one product over 56 months with no discernible difference indicating very good stability and reproducibility. Since the drilling process only exposes a small surface area of the product while the remainder is coated with a reduced permeability enteric film coating, the shelf life does not appear to be, nor is expected to be, any different to a cosmetically film coated product.

Dedusting and metal checking are used as part of manufacturing, similarly to compression, reducing potential operator exposure and contamination downstream. The potential for product damage on downstream processing, such as packaging, was investigated showing that, using typical equipment, the process was optimized to eliminate potential defects.

How do you scale up the process for commercial production?


Figure 5: Development equipment with on-line inspection systems.
Post PoC, a development machine has been purpose built to manufacture these products (see Figure 5). This machine will manufacture up to 10,000 units per hour with online inspection of the product quality attributes impacting performance.


Figure 6: Commercial manufacturing equipment with online inspection systems.
For commercial production, GSK uses machines that are currently installed in its global manufacturing facility in North Carolina (see Figure 6). These machines have the same functionality and process parameters as the small-scale equipment, thereby eliminating scale-up and increasing output (approximately 120,000 units per hour). The process is scale-independent, and the final development process is transferred directly to the commercial machines. The current manufacturing process exhibits consistent content uniformity with good variability (mean = 99%, standard deviation = 0.82, based on 14 commercial batches).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here